EDITAS MEDICINE, INC. Operating Lease, Payments
EDITAS MEDICINE, INC. (EDIT) reported Operating Lease, Payments of $4.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- EDITAS MEDICINE, INC. operating lease, payments for the quarter ending 2026-06-30 was $2.01M, a 64.43% decline year-over-year.
- EDITAS MEDICINE, INC. operating lease, payments for the quarter ending 2026-03-31 was $2.00M, a 62.93% decline year-over-year.
- EDITAS MEDICINE, INC. operating lease, payments for the quarter ending 2025-12-31 was $1.98M, a 66.41% decline year-over-year.
- EDITAS MEDICINE, INC. operating lease, payments for the quarter ending 2025-09-30 was $1.94M, a 60.18% decline year-over-year.
- EDITAS MEDICINE, INC. operating lease, payments for fiscal 2025 was $14.97M, a 18.86% decline from fiscal 2024.
- EDITAS MEDICINE, INC. operating lease, payments for fiscal 2024 was $18.45M, a 48.43% increase from fiscal 2023.
- EDITAS MEDICINE, INC. operating lease, payments for fiscal 2023 was $12.43M, a 16.32% decline from fiscal 2022.
- EDITAS MEDICINE, INC. operating lease, payments for fiscal 2022 was $14.85M, a 13.42% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.01M 10-Q · filed 2026-08-05 | $5.99M derived: sum of 3 quarters · filed 2026-08-05 | $7.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-05 | $3.98M derived: sum of 2 quarters · filed 2026-05-05 | $5.92M derived: sum of 3 quarters · filed 2026-05-05 | $11.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.92M derived: sum of 2 quarters · filed 2026-03-09 | $9.56M derived: sum of 3 quarters · filed 2026-08-05 | $14.97M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.59M derived: sum of 2 quarters · filed 2026-08-05 | $12.99M 10-Q · filed 2025-11-10 | $18.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.05M 10-Q · filed 2026-08-05 | $16.93M derived: sum of 3 quarters · filed 2026-08-05 | $21.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.41M 10-Q · filed 2026-05-05 | $11.29M derived: sum of 2 quarters · filed 2026-05-05 | $16.17M derived: sum of 3 quarters · filed 2026-05-05 | $20.01M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $10.76M derived: sum of 2 quarters · filed 2026-03-09 | $14.60M derived: sum of 3 quarters · filed 2026-03-09 | $18.45M 10-K · filed 2026-03-09 |
| 2024-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.72M derived: sum of 2 quarters · filed 2025-11-10 | $12.56M 10-Q · filed 2025-11-10 | $15.89M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $3.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $7.68M 10-Q · filed 2025-08-12 | $11.01M derived: sum of 3 quarters · filed 2025-08-12 | $14.37M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.85M 10-Q · filed 2025-05-12 | $7.17M derived: sum of 2 quarters · filed 2025-05-12 | $10.54M derived: sum of 3 quarters · filed 2025-05-12 | $12.38M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $6.69M derived: sum of 2 quarters · filed 2025-03-05 | $8.53M derived: sum of 3 quarters · filed 2025-03-05 | $12.43M 10-K · filed 2025-03-05 |
| 2023-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $5.21M derived: sum of 2 quarters · filed 2024-11-04 | $9.10M 10-Q · filed 2024-11-04 | $12.06M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.74M 10-Q · filed 2024-08-07 | $8.70M derived: sum of 3 quarters · filed 2025-03-05 | $13.50M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $3.90M 10-Q · filed 2024-05-08 | $6.85M derived: sum of 2 quarters · filed 2025-03-05 | $11.66M derived: sum of 3 quarters · filed 2025-03-05 | $15.00M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $7.76M derived: sum of 2 quarters · filed 2025-03-05 | $11.11M derived: sum of 3 quarters · filed 2025-03-05 | $14.85M 10-K · filed 2025-03-05 |
| 2022-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $8.15M derived: sum of 2 quarters · filed 2023-11-03 | $11.89M 10-Q · filed 2023-11-03 | $16.07M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $7.09M 10-Q · filed 2023-08-02 | $11.27M derived: sum of 3 quarters · filed 2024-02-28 | $13.45M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $3.75M 10-Q · filed 2023-05-05 | $7.92M derived: sum of 2 quarters · filed 2024-02-28 | $10.11M derived: sum of 3 quarters · filed 2024-02-28 | $12.59M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.36M derived: sum of 2 quarters · filed 2024-02-28 | $8.85M derived: sum of 3 quarters · filed 2024-02-28 | $13.09M 10-K · filed 2024-02-28 |
| 2021-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $4.67M derived: sum of 2 quarters · filed 2022-11-02 | $8.92M 10-Q · filed 2022-11-02 | $10.92M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $6.73M 10-Q · filed 2022-08-03 | $8.73M derived: sum of 3 quarters · filed 2023-02-22 | $11.37M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $4.25M 10-Q · filed 2022-05-04 | $6.25M derived: sum of 2 quarters · filed 2023-02-22 | $8.88M derived: sum of 3 quarters · filed 2023-02-22 | $11.47M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $4.63M derived: sum of 2 quarters · filed 2023-02-22 | $7.22M derived: sum of 3 quarters · filed 2023-02-22 | $9.76M 10-K · filed 2023-02-22 |
| 2020-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.22M derived: sum of 2 quarters · filed 2021-11-09 | $7.76M 10-Q · filed 2021-11-09 | $9.12M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.13M 10-Q · filed 2021-08-05 | $6.49M derived: sum of 3 quarters · filed 2022-02-24 | $8.01M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $2.54M 10-Q · filed 2021-05-06 | $3.90M derived: sum of 2 quarters · filed 2022-02-24 | $5.42M derived: sum of 3 quarters · filed 2022-02-24 | $6.78M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.88M derived: sum of 2 quarters · filed 2022-02-24 | $4.25M derived: sum of 3 quarters · filed 2022-02-24 | $5.97M 10-K · filed 2022-02-24 |
| 2019-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.88M derived: sum of 2 quarters · filed 2020-11-06 | $4.60M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $3.09M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $1.72M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |